Targeting PD-1 variants for treatment of cancer

• US 9,067,998 B1
• Filed: 11/10/2014
• Issued: 06/30/2015
• Est. Priority Date: 07/15/2014
• Status: Active Grant

• Current Assignee: Kymab Limited (Sanofi )
• Original Assignee: Kymab Limited (Sanofi )
• Inventors: Clube, Jasper Rupert
• Primary Examiner(s): WEN, SHARON X
• Application Number:
  US14/537,403
• Time in Patent Office: 232 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/172 Haplotypes

Abstract

The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.

Claims

1. A method of treating a solid tumor;

melanoma;

renal cell carcinoma;

non small-cell lung cancer;

bladder cancer;

Hodgkin'"'"'s lymphoma;

or gastric cancer in a human by targeting PD-1 in the human, the method comprising administering an antibody or antibody fragment to the human, wherein the antibody or antibody fragment specifically binds a PD-1 encoded by a PD-1 nucleotide sequence comprising a SNP selected from the group consisting of;

rs7568402;

rs28699177;

rs28542728;

rs118117097;

rs28570544;

rs118027315;

rs191919871;

rs6707556;

rs142909968;

rs36084323;

rs10204225;

rs11568821;

rs2227981; and

rs2227982;

wherein the antibody or antibody fragment comprises a human gamma-4 heavy chain constant region that comprises an amino acid selected from the group consisting of;

a Leu at position 189 shown in SEQ ID NO;

73 and an Arg at position 289 shown in SEQ ID NO;

73; and

wherein said human comprises

(i) an IGHG4*01 human heavy chain constant region gene segment, or the human expresses antibodies comprising human gamma-4 heavy chain constant regions comprising said selected amino acid; and

(ii) a PD-1 nucleotide sequence comprising said selected SNP.

2. The method of claim 1, wherein the selected SNP is a nucleotide corresponding to SNP rs36084323, rs10204225, rs11568821, rs2227981 or rs2227982.

3. The method of claim 1, wherein said human is homozygous for said selected SNP.

4. The method of claim 1, wherein the ligand comprises an IGHG4*01 human heavy chain constant region;

optionally comprising 228Pro and 235Glu.

5. The method of claim 1, comprising, before said administering, selecting a human comprising said PD-1 nucleotide sequence of (ii), wherein the human is the human of claim 1.

6. The method of claim 1, wherein the human has been determined to comprise said PD-1 nucleotide sequence of (ii).

7. The method of claim 1, comprising the step of determining that the human comprises said PD-1 nucleotide sequence of (ii), optionally, wherein the determining step is performed before administration of the antibody to the human.

8. The method of claim 7, wherein the step of determining comprises assaying a biological sample from the human for a PD-1 nucleotide sequence comprising said selected SNP.

9. The method of claim 8, wherein the assaying comprises contacting the biological sample with

a. at least one oligonucleotide probe comprising a sequence of at least 10 contiguous nucleotides that can specifically hybridize to and identify in the biological sample a nucleotide sequence comprising said selected SNP or that specifically hybridizes to an antisense of said sequence, wherein said nucleic acid hybridizes to said selected SNP or hybridizes to an antisense sequence thereby forming a complex when at least one nucleotide sequence comprising said selected SNP is present;

and/or

b. at least one oligonucleotide probe comprising a sequence of at least 10 contiguous nucleotides of a nucleotide sequence comprising said selected SNP or comprising an antisense sequence of said contiguous nucleotides, wherein said sequence of contiguous nucleotides comprises said selected SNP thereby forming a complex when the nucleotide sequence comprising said selected SNP is present; and

c. detecting the presence or absence of the complex, wherein detecting the presence of the complex determines that the human comprises a PD-L1 nucleotide sequence comprising said selected SNP.

10. The method of claim 8, wherein the assaying comprises nucleic acid amplification and optionally one or more methods selected from sequencing, next generation sequencing, nucleic acid hybridization, and allele-specific amplification and/or wherein the assaying is performed in a multiplex format.

11. The method of claim 1, wherein said human is or has been further determined to be substantially resistant a chemotherapy treatment.

12. The method of claim 1, wherein said human is receiving or has received a chemotherapy treatment or has reduced responsiveness to a chemotherapy treatment.

13. The method of claim 8, wherein said biological sample comprises serum, blood, faeces, tissue, a cell, urine and/or saliva of said human.

14. The method of claim 1, wherein said antibody or antibody fragment is administered by intravenous or subcutaneous injection and/or is comprised in an injectable preparation.

15. The method of claim 1, wherein the antibody or antibody fragment is a human antibody or antibody fragment.